| 摘要 |
PURPOSE:To obtain the titled pharmaceutical consisting of a clathrate complex prepared by including a drug in a hydrophobic cyclodextrin derivative. CONSTITUTION:A sustained release pharmaceutical obtained from a clathrate complex prepared by including a drug, e.g. analgesic agent, antipyretic agent, antiarrhythmic agent, vitamins, anti-inflammatory agent, coronary arterial vasodilator, venous vasodilator, bronchodilator, etc., in a hydrophobic cyclodextrin derivative, e.g. heptakis-(2,3-di-O-ethyl)-beta-cyclodextrin, heptakis-(2,6- di-O-ethyl)-beta-cyclodextrin, heptakis-(2,3,6-tri-O-ethyl)-beta-cyclodextrin or a blend thereof. Furthermore, release control of the drug can be optionally carried out by successfully combining the above-mentioned three kinds in the case of ethylated cyclodextrin. The clathrate complex has 1:1-1:10 molar ratio of guest molecules (drug) to host molecules (cyclodextrin).
|
